LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate.

abstract：:The pharmacokinetic parameters of the alkylating agent melphalan were determined in 15 children and 11 adults with advanced malignant solid tumors. High IV bolus doses of 140 mg/m2 were given under standard hyperhydration conditions and followed by autologous bone marrow grafting. In all cases the time-concentration c...

journal_title：Cancer chemotherapy and pharmacology

authors： Ardiet C,Tranchand B,Biron P,Rebattu P,Philip T

更新日期：1986-01-01 00:00:00

abstract：:Sorafenib (Nexavar®) is currently the only FDA-approved small molecule targeted therapy for advanced hepatocellular carcinoma. The use of structural analogues and derivatives of sorafenib has enabled the elucidation of critical targets and mechanism(s) of cell death for human cancer lines. We previously performed a st...

journal_title：Cancer chemotherapy and pharmacology

authors： Wecksler AT,Hwang SH,Liu JY,Wettersten HI,Morisseau C,Wu J,Weiss RH,Hammock BD

更新日期：2015-01-01 00:00:00

abstract：PURPOSE:SU5416 is a novel small organic molecule that non-competitively inhibits the phosphorylation of the VEGF tyrosine kinase receptor, Flk-1. This phase IB study was performed to determine the safety, pharmacokinetics, and preliminary efficacy of the combination of SU5416 and paclitaxel in recurrent or metastatic c...

journal_title：Cancer chemotherapy and pharmacology

authors： Cooney MM,Tserng KY,Makar V,McPeak RJ,Ingalls ST,Dowlati A,Overmoyer B,McCrae K,Ksenich P,Lavertu P,Ivy P,Hoppel CL,Remick S

更新日期：2005-03-01 00:00:00

abstract：:Sandostatin immediate release (IR) is frequently used to treat patients with carcinoid tumors. However, some patients are unable to tolerate the immediate side effects of sandostatin IR leading to discontinuation of the drug. There is no literature available to guide the management of patients' sensitivity/intolerance...

journal_title：Cancer chemotherapy and pharmacology

authors： Vinjamaram S,Iyer R

更新日期：2011-07-01 00:00:00

abstract：PURPOSE:Gemcitabine/cisplatin combination therapy has been the standard palliative chemotherapy for patients with advanced biliary tract cancer (BTC). We aimed to evaluate the efficacy and safety of adding S-1 to gemcitabine/cisplatin combination therapy for patients with advanced BTC. METHODS:Patients with histologic...

journal_title：Cancer chemotherapy and pharmacology

authors： Kanai M,Hatano E,Kobayashi S,Fujiwara Y,Marubashi S,Miyamoto A,Shiomi H,Kubo S,Ikuta S,Yanagimoto H,Terajima H,Ikoma H,Sakai D,Kodama Y,Seo S,Morita S,Ajiki T,Nagano H,Ioka T

更新日期：2015-02-01 00:00:00

abstract：:A phase II trial of idarubicin was performed in 24 patients with advanced lymphoma. The drug was administered in a dose of 10-15 mg/m2 i.v. or 15-70 mg/m2 p.o. (single dose) every 3 weeks. There were four partial responses and four minor responses. All but one of the responders had received prior doxorubicin therapy. ...

journal_title：Cancer chemotherapy and pharmacology

authors： Gillies H,Liang R,Rogers H,Harper P,Parapia L,Cox G,Johnson S

更新日期：1988-01-01 00:00:00

abstract：INTRODUCTION:A combined therapy MEK inhibitor, Cobimetinib (CB) and BRAF inhibitor, Vemurafenib (VMF), results in an improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma. VMF skin adverse effects attributed to ERK paradoxical activation are decreased by the adjunction of CB...

journal_title：Cancer chemotherapy and pharmacology

authors： Teuma C,Pelletier S,Amini-Adl M,Perier-Muzet M,Maucort-Boulch D,Thomas L,Laville M,Fouque D,Dalle S

更新日期：2017-05-01 00:00:00

abstract：PURPOSE:The purpose of this article is to report the first case of markedly increased anticoagulant activity of warfarin when used in combination with doxifluridine, given as a replacement for capecitabine. METHODS:International normalized ratio (INR) of a 73-year-old female patient receiving warfarin was increased af...

journal_title：Cancer chemotherapy and pharmacology

authors： Nakajima M,Genda T,Suehira M,Satoh H,Miki A,Hori S,Sawada Y

更新日期：2010-10-01 00:00:00

abstract：PURPOSE:This phase I study was undertaken to evaluate the safety and tolerability of prolonged infusional etoposide, and to evaluate its pharmacokinetic/pharmacodynamic profile in patients with advanced cancer. METHODS:A group of 17 patients received a 7-day infusion of etoposide (schedule A) every 21 days at doses fr...

journal_title：Cancer chemotherapy and pharmacology

authors： Robert F,Chen S,Miller AA,Lee BC,Molthrop DC,Wheeler RH

更新日期：1996-01-01 00:00:00

abstract：:Sixty-seven patients with acute nonlymphoblastic leukemia (ANLL) and above the age of 60 years were randomly allocated to treatment with either prednimustine + vincristine or cycles with cytosine arabinoside and thioguanine. Of the 67 patients, 13 (19%) entered a complete remission and four a partial remission. Of 33 ...

journal_title：Cancer chemotherapy and pharmacology

authors： Lönnqvist B,Andersson B,Björkholm M,Engstedt L,Gahrton G,Hast R,Holm G,Killander A,Lantz B,Lockner D,Mellstedt H,Palmblad J,Paul C,Peterson C,Simonsson B,Stalfelt AM,Udén AM,Wadman B,Oberg G

更新日期：1982-01-01 00:00:00

abstract：:Resistance to the clinically used platinum-based drugs cisplatin and carboplatin represents a major limitation to their clinical effectiveness. Using cisplatin-sensitive and -resistant human ovarian carcinoma cell lines previously characterized in terms of their major underlying mechanisms of resistance, we attempted ...

journal_title：Cancer chemotherapy and pharmacology

authors： Sharp SY,Mistry P,Valenti MR,Bryant AP,Kelland LR

更新日期：1994-01-01 00:00:00

abstract：:To enable the treatment of hepatic metastasis with higher, theoretically more effective, doses of systemically toxic anticancer drugs, an isolated liver perfusion (ILP) technique was developed in WAG/Ola rats. First, in a toxicity study the maximally tolerated dose (MTD) of mitomycin C (MMC) was determined for a 25-mi...

journal_title：Cancer chemotherapy and pharmacology

authors： Marinelli A,Pons DH,Vreeken JA,Nagesser SK,Kuppen PJ,Tjaden UR,van de Velde CJ

更新日期：1991-01-01 00:00:00

abstract：PURPOSE:Thalidomide has recently shown significant promise in the treatment of some types of cancer, and trials in combination with conventional chemotherapy are being undertaken. We wished to determine whether thalidomide potentiated the effect of cyclophosphamide, a commonly used cytotoxic drug, in a murine tumour mo...

journal_title：Cancer chemotherapy and pharmacology

authors： Ding Q,Kestell P,Baguley BC,Palmer BD,Paxton JW,Muller G,Ching LM

更新日期：2002-09-01 00:00:00

abstract：PURPOSE:We report on a statistical method for grouping anti-cancer drugs (GRAD) in single mouse trials (SMT). The method assigns candidate drugs into groups that inhibit or do not inhibit tumor growth in patient-derived xenografts (PDX). It determines the statistical significance of the group assignments without replic...

journal_title：Cancer chemotherapy and pharmacology

authors： Gordon D,Axelrod DE

更新日期：2019-12-01 00:00:00

abstract：:The effects of anticalmodulin agents, namely trifluoperazine (TFP) and two naphthalene sulfonamide derivatives (W-7 and W-13), were tested on the growth of a human breast cancer cell line (MDA-MB-231) using a soft agar clonogenic assay. The results of this in vitro study reveal that TFP, W-7, and W-13 had the ability ...

journal_title：Cancer chemotherapy and pharmacology

authors： Wei JW,Hickie RA,Klaassen DJ

更新日期：1983-01-01 00:00:00

abstract：:A variety of purine analogs inhibit the growth and induce the differentiation of human promyelocytic leukemia (HL-60) cells that lack the purine salvage enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT). Mechanisms by which purine analogs induce differentiation offer unique potential for cancer chemotherap...

journal_title：Cancer chemotherapy and pharmacology

authors： Gibboney DS,French BT,Patrick DE,Trewyn RW

更新日期：1989-01-01 00:00:00

abstract：PURPOSE:To investigate the synergistic cytotoxicity of TRAIL in combination with chemotherapeutic agents in A549 cell lines, we systematically evaluated the cytotoxicity of TRAIL alone and TRAIL in combination with cisplatin, paclitaxel (Taxol) or actinomycin D in A549 cell lines in vitro and in vivo, and whether the s...

journal_title：Cancer chemotherapy and pharmacology

authors： Fan QL,Zou WY,Song LH,Wei W

更新日期：2005-02-01 00:00:00

abstract：PURPOSE:6-Gingerol, a major biochemical and pharmacological active ingredient of ginger, has shown anti-inflammatory and antitumor activities against various cancers. Searching for natural products with fewer side effects for developing adjunctive therapeutic options is necessary. METHODS:The effects of 6-gingerol on ...

journal_title：Cancer chemotherapy and pharmacology

authors： Xu S,Zhang H,Liu T,Yang W,Lv W,He D,Guo P,Li L

更新日期：2020-02-01 00:00:00

abstract：PURPOSE:To assess the effect of elotuzumab on corrected QT (QTc) intervals and cardiac safety. METHODS:Patients with high-risk smoldering multiple myeloma who had been treated with elotuzumab monotherapy (10 or 20 mg/kg) in Study CA204011 (NCT01441973) underwent electrocardiogram (ECG) examination over 8-10 weeks (tre...

journal_title：Cancer chemotherapy and pharmacology

authors： Passey C,Darbenzio R,Jou YM,Lynch M,Gupta M

更新日期：2016-12-01 00:00:00

abstract：BACKGROUND:Chemotherapy for breast cancer is associated with a high risk of neutropenia. Pegfilgrastim reduces the risk of neutropenic fever but commonly causes bone pain. OBJECTIVE:Evaluate whether a reduced dose of pegfilgrastim (3 mg) reduced the frequency of bone pain without compromising efficacy. METHODS:Record...

journal_title：Cancer chemotherapy and pharmacology

authors： Lower EE,Charif M,Bartelt M

更新日期：2018-07-01 00:00:00

abstract：:Levels of radioactivity and total anthracycline fluorescence in tissues of A/JAX mice were compared 1 h after IV administration of unlabeled or [14C]-labeled AD 32 (50 mg/kg). Highest levels of both fluorescence and radioactivity were found in the small intestine (including contents) and liver, a result consistent wit...

journal_title：Cancer chemotherapy and pharmacology

authors： Israel M,Karkowsky AM,Khetarpal VK

更新日期：1981-01-01 00:00:00

abstract：BACKGROUND:Cetuximab and panitumumab are chimeric and fully human monoclonal antibodies, respectively, against epidermal growth factor receptor used in the treatment of metastatic colorectal cancer (mCRC). Incidence of documented infusion reaction (IR) is more common with cetuximab (all grades [g]: 15-21%, g 3/4: 2-5%)...

journal_title：Cancer chemotherapy and pharmacology

authors： Saif MW,Syrigos KI,Hotchkiss S,Shanley J,Grasso J,Ferencz TM,Syrigos K,Shah MM

更新日期：2009-12-01 00:00:00

abstract：PURPOSE:To establish the cytochrome P450 (CYP) isozymes involved in the metabolism of the alkylating agent, thiotepa, to the pharmacologically active metabolite, TEPA. METHODS:In vitro chemical inhibition studies were conducted by incubating thiotepa and pooled human hepatic microsomes in the presence of known inhibit...

journal_title：Cancer chemotherapy and pharmacology

authors： Jacobson PA,Green K,Birnbaum A,Remmel RP

更新日期：2002-06-01 00:00:00

abstract：PURPOSE:The ERCC1-XPF 5'-3' DNA endonuclease complex is involved in the nucleotide excision repair pathway and in the DNA inter-strand crosslink repair pathway, two key mechanisms modulating the activity of chemotherapeutic alkylating agents in cancer cells. Inhibitors of the interaction between ERCC1 and XPF can be us...

journal_title：Cancer chemotherapy and pharmacology

authors： Ciniero G,Elmenoufy AH,Gentile F,Weinfeld M,Deriu MA,West FG,Tuszynski JA,Dumontet C,Cros-Perrial E,Jordheim LP

更新日期：2021-01-05 00:00:00

abstract：:The subjects were 35 patients with unresectable hepatocellular carcinoma. The patients were divided into a transcatheter arterial embolization group (TAE group, 18 cases) and a combination therapy group receiving both TAE and percutaneous ethanol injection therapy (TAE+PEIT group, 17 cases). The 50% survival period wa...

journal_title：Cancer chemotherapy and pharmacology

authors： Tateishi H,Kinuta M,Furukawa J,Takata N,Maruyama H,Oi H,Yayoi E,Okamura J

更新日期：1994-01-01 00:00:00

abstract：PURPOSE:The plasma and cerebrospinal fluid (CSF) pharmacokinetics of the camptothecin analogs, 9-aminocamptothecin (9-AC) and irinotecan, were studied in a nonhuman primate model to determine their CSF penetration. METHODS:9-AC, 0.2 mg/kg (4 mg/m2) or 0.5 mg/kg (10 mg/m2), was infused intravenously over 15 min and iri...

journal_title：Cancer chemotherapy and pharmacology

authors： Blaney SM,Takimoto C,Murry DJ,Kuttesch N,McCully C,Cole DE,Godwin K,Balis FM

更新日期：1998-01-01 00:00:00

abstract：PURPOSE:To investigate the effects of genetic polymorphisms on morphine-induced adverse events in cancer patients. METHODS:We examined the relation of morphine-related adverse events to polymorphisms in UDP-glucuronosyltransferase (UGT) 2B7, ATP-binding cassette, sub-family B, number 1 (ABCB1), and μ-opioid receptor 1...

journal_title：Cancer chemotherapy and pharmacology

authors： Fujita K,Ando Y,Yamamoto W,Miya T,Endo H,Sunakawa Y,Araki K,Kodama K,Nagashima F,Ichikawa W,Narabayashi M,Akiyama Y,Kawara K,Shiomi M,Ogata H,Iwasa H,Okazaki Y,Hirose T,Sasaki Y

更新日期：2010-01-01 00:00:00

abstract：OBJECTIVES:The aim of this phase II study was to evaluate the response rate to gemcitabine combined with cisplatin in patients with locally advanced, metastatic or recurrent biliary tract cancer who had received no prior chemotherapy. METHODS:The treatment consisted of cisplatin 70 mg/m(2) in intravenous infusion foll...

journal_title：Cancer chemotherapy and pharmacology

authors： Lee J,Kim TY,Lee MA,Ahn MJ,Kim HK,Lim HY,Lee NS,Park BJ,Kim JS,Korean Cancer Study Group.

更新日期：2008-01-01 00:00:00

abstract：:In this review of the management of invasive carcinoma of the bladder the results of primary and systemic therapies are evaluated in the light of the natural history of the disease. The clinical and pathological causes of treatment failure are assessed in an attempt to identify new approaches that may be used in the f...

journal_title：Cancer chemotherapy and pharmacology

authors： Bush H,Thatcher N,Barnard R

更新日期：1979-01-01 00:00:00

abstract：PURPOSE:The absorption, distribution, metabolism, and excretion of the hedgehog pathway inhibitor sonidegib (LDE225) were determined in healthy male subjects. METHODS:Six subjects received a single oral dose of 800 mg ¹⁴C-sonidegib (74 kBq, 2.0 µCi) under fasting conditions. Blood, plasma, urine, and fecal samples wer...

journal_title：Cancer chemotherapy and pharmacology

authors： Zollinger M,Lozac'h F,Hurh E,Emotte C,Bauly H,Swart P

更新日期：2014-07-01 00:00:00